Inspire Medical Systems (NYSE:INSP) Given New $280.00 Price Target at Truist Financial

Inspire Medical Systems (NYSE:INSPFree Report) had its target price increased by Truist Financial from $265.00 to $280.00 in a report published on Wednesday, Benzinga reports. Truist Financial currently has a buy rating on the stock.

Other research analysts also recently issued reports about the company. Mizuho upped their price objective on Inspire Medical Systems from $225.00 to $250.00 and gave the stock a buy rating in a research note on Wednesday. Jefferies Financial Group started coverage on Inspire Medical Systems in a research note on Friday, January 19th. They set a buy rating and a $245.00 price objective for the company. KeyCorp started coverage on Inspire Medical Systems in a research report on Tuesday. They set an overweight rating and a $278.00 price target for the company. SVB Leerink started coverage on Inspire Medical Systems in a research report on Monday, October 16th. They set a market perform rating and a $159.00 price target for the company. Finally, Leerink Partnrs reiterated a market perform rating on shares of Inspire Medical Systems in a research report on Monday, October 16th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $272.92.

Check Out Our Latest Stock Analysis on INSP

Inspire Medical Systems Price Performance

NYSE INSP opened at $202.16 on Wednesday. The firm has a market capitalization of $5.97 billion, a P/E ratio of -178.90 and a beta of 1.42. Inspire Medical Systems has a 1-year low of $123.27 and a 1-year high of $330.00. The business’s 50-day simple moving average is $190.38 and its 200-day simple moving average is $194.45.

Inspire Medical Systems (NYSE:INSPGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.53. Inspire Medical Systems had a negative return on equity of 6.32% and a negative net margin of 5.75%. The company had revenue of $192.51 million for the quarter, compared to the consensus estimate of $186.75 million. During the same period in the previous year, the business earned $0.10 EPS. Inspire Medical Systems’s revenue for the quarter was up 39.6% compared to the same quarter last year. On average, equities research analysts expect that Inspire Medical Systems will post -1.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank boosted its position in Inspire Medical Systems by 1.9% in the 2nd quarter. Swiss National Bank now owns 63,500 shares of the company’s stock valued at $20,615,000 after buying an additional 1,200 shares during the last quarter. SG Americas Securities LLC bought a new position in Inspire Medical Systems in the 3rd quarter valued at $1,452,000. Cetera Advisor Networks LLC boosted its position in Inspire Medical Systems by 18.6% in the 2nd quarter. Cetera Advisor Networks LLC now owns 1,124 shares of the company’s stock valued at $365,000 after buying an additional 176 shares during the last quarter. Qsemble Capital Management LP bought a new position in Inspire Medical Systems in the 3rd quarter valued at $823,000. Finally, Beacon Investment Advisory Services Inc. boosted its position in Inspire Medical Systems by 1,177.2% in the 3rd quarter. Beacon Investment Advisory Services Inc. now owns 9,145 shares of the company’s stock valued at $1,815,000 after buying an additional 8,429 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

(Get Free Report)

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

Featured Stories

Analyst Recommendations for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.